Purdue Appeals Par's Defeat Of Ultram Patents
With its control over Ultram ER in peril, Purdue Pharma Products LP has appealed a federal judge's August decision that invalidated Purdue's patents for the painkiller and cleared the way for...To view the full article, register now.
Already a subscriber? Click here to view full article